Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan-Feb:38:107337.
doi: 10.1016/j.biotechadv.2019.01.004. Epub 2019 Jan 8.

Current status and contemporary approaches to the discovery of antitumor agents from higher plants

Affiliations
Review

Current status and contemporary approaches to the discovery of antitumor agents from higher plants

Garima Agarwal et al. Biotechnol Adv. 2020 Jan-Feb.

Abstract

Higher plant constituents have afforded clinically available anticancer drugs. These include both chemically unmodified small molecules and their synthetic derivatives currently used or those in clinical trials as antineoplastic agents, and an updated summary is provided. In addition, botanical dietary supplements, exemplified by mangosteen and noni constituents, are also covered as potential cancer chemotherapeutic agents. Approaches to metabolite purification, rapid dereplication, and biological evaluation including analytical hyphenated techniques, molecular networking, and advanced cellular and animal models are discussed. Further, enhanced and targeted drug delivery systems for phytochemicals, including micelles, nanoparticles and antibody drug conjugates (ADCs) are described herein.

Keywords: 2D and 3D cell cultures; Antibody-drug conjugates (ADCs).; Botanical dietary supplements; Cancer chemotherapeutic agents; Dereplication analytical methods; Micelles; Molecular networking; Nanoparticles; Plant natural products.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Plant-derived natural products used as antitumor drugs
Figure 2.
Figure 2.
Examples of other plant-derived secondary metabolites and selected derivatives with antitumor activity
Figure 3.
Figure 3.
Examples of bioactive xanthones from mangosteen (Garcinia mangostana)
Figure 4.
Figure 4.
Selected chemical constituents of noni (Morinda citrifolia)
Figure 5
Figure 5
Summary of advantages and disadvantages of using 2D cell culture
Figure 6.
Figure 6.
Summary of advantages and disadvantages of using 3D cell culture
Figure 7.
Figure 7.
Examples of micelle designs
Figure 8.
Figure 8.
Major components of ADCs. Included is each component’s main purpose, requirements to be a candidate for an ADC, and some examples based on approved ADCs (Note: the purpose, requirements and examples stated are not comprehensive but only representative of the most common ones; see the cited references for additional information).
Figure 9.
Figure 9.
A) Structure of maytansine and analogues (DM1 and DM4) common in ADCs. B) Structure of ado-trastuzumab emtansine (Kadcyla®) (Note: the n, i.e., DAR, given is an approximate value and may vary).
Figure 10.
Figure 10.
A) Structure of silvestrol. B) ADCs (ADC-103 and ADC-104) conjugated at position 2 of silvestrol. C) ADCs (ADC-105 and ADC-108) conjugated at position 6′′′ of silvestrol.

Similar articles

Cited by

References

    1. Abou Assi R., Darwis Y, Abdulbaqi IM, Khan AA, Vuanghao L, Laghari MH, 2017. Morinda citrifolia (noni): a comprehensive review on its industrial uses, pharmacological activities, and clinical trials. Arabian J. Chem 10, 691–707.
    1. Afsar T, Trembley JH, Salomon CE, Razak S, Khan MR, Ahmed K, 2016. Growth inhibition and apoptosis in cancer cells induced by polyphenolic compounds of Acacia hydaspica: involvement of multiple signal transduction pathways. Sci. Rep 6, 23077. - PMC - PubMed
    1. Aisha AFA, Abdulmajid AMS, Ismail Z, Alrokayan SA, Abu-Salah KM, 2015. Development of polymeric nanoparticles of Garcinia mangostana xanthones in eudragit RL100/RS100 for anti-colon cancer drug delivery. J. Nanomater 2015, 701979.
    1. Alexis F, Rhee J-W, Richie JP, Radovic-Moreno AF, Langer R, Farokhzad OC, 2008. New frontiers in nanotechnology for cancer treatment. Urol. Oncol.: Semin. Orig. Invest 26, 74–85. - PubMed
    1. Allard P-M, Peresse T, Bisson J, Gindro K, Marcourt L, Pham VC, Roussi F, Litaudon M, Wolfender J-L, 2016. Integration of molecular networking and in-silico MS/MS fragmentation for natural products dereplication. Anal. Chem 88, 3317–3323. - PubMed

Publication types

LinkOut - more resources